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The effects of the antidepressant venlafaxine (VEN-225 mg daily) and transdiagnostic cognitive behav-
ioral treatment (CBT) alone and in combination on alcohol intake in subjects with co-morbid alcohol use
disorders (AUDs) and anxiety disorders were compared. Drinking outcomes and anxiety were assessed
for 81 subjects treated for 11 weeks with one of 4 conditions: 1) VENeCBT, 2) VEN-Progressive Muscle
Relaxation therapy (PMR), 3) Placebo (PLC)-CBT and 4) a comparison group of PLC-PMR. For subjects who
reported taking at least one dose of study medication, the Time  Group interaction was signiﬁcant for
percent days of heavy drinking and drinks consumed per day. For the measure of percent days heavy
drinking, the paired comparison of PLC-CBT versus PLC-PMR group indicated that the PLC-CBT group had
greater drinking reductions, whereas other groups were not superior to the comparison group. In Week
11, the proportion of subjects in the PLC-CBT group that had a 50% reduction from baseline in percent
days heavy drinking was signiﬁcantly greater than those in the comparison group. Of the 3 “active
treatment” groups only the PLC-CBT group had signiﬁcantly decreased heavy drinking when contrasted
to the comparison group. This ﬁnding suggests that the transdiagnostic CBT approach of Barlow and
colleagues may have value in the management of heavy drinking in individuals with co-morbid alco-
holism and anxiety.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Alcohol use disorders (AUDs) have been reported to occur with a
12-month prevalence of almost 9% of the adult population in the
United States (Grant et al., 2004; Hasin, Stinson, Ogburn, & Grant,
2007). In excess of 33% of treatment seeking individuals with an
AUD may have at least one concurrent independent anxietyf Medicine, Suite 914, Doctors
18, United States.
r Ltd. Open access under CC BY-NC-Ndisorder (Grant et al., 2004). Panic and social phobia are both
predictors of later alcohol use problems in adolescents and young
adults (Zimmermann et al., 2003). Recent work suggests increases
in the number of anxiety and other internalizing disorders,
including depression and dysthymia, are directly related to in-
creases in the prevalence of alcohol dependence (Kushner et al.,
2012).
The results of several studies suggest that the existence of a co-
morbid anxiety disorder can have a signiﬁcant inﬂuence on the
outcome of treatment of AUDs. In one study, social anxiety limited
the willingness of individuals with AUDs to seek some forms of
treatment for their drinking problems (Book, Thomas, Dempsey,
Randall, & Randall, 2009). In another investigation, the severity of
anxiety symptoms predicted recurrence of alcohol dependence in
remitted patients (Boschloo et al., 2012). Phobic anxiety disordersD license.
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and discontinuation of treatment (Haver & Gjestad, 2005). Finally,
there is evidence that social phobia is a predictor of return drinking
after completion of treatment and panic disorder is a predictor of
post-treatment alcohol dependence (Kushner et al., 2005).
Based on this empirical and theoretical literature, treatments for
alcohol dependence that target anxiety as a mediator of treatment
gains and/or relapse are appealing. Empirical evaluations of
anxiety-focused treatments among substance-dependent patients
(including alcoholics) have yielded mixed results. Several studies
have called into question the utility of this approach (Bowen,
D’Arcy, Keegan, & Senthilselvan, 2000; Ormrod & Budd, 1991;
Schadé et al., 2005). In contrast, other researchers have reported
that addressing symptoms of anxiety could be important for the
treatment of alcoholism (Fals-Stewart & Schafer, 1992; Modesto-
Lowe & Kranzler, 1999).
In addition to behavioral therapies some investigators have
examined the use of selective serotonin reuptake inhibitors (SSRIs),
which have anxiolytic effects, in the treatment of alcohol use dis-
orders in individuals with co-morbid anxiety disorders. In one
study, although anxiety symptoms improved in subjects treated
with the SSRI paroxetine, alcohol consumption was not meaning-
fully altered (Thomas, Randall, Book, & Randall, 2008). In another
investigation, the addition of the SSRI ﬂuvoxamine to the treatment
regime of cognitive behavioral treatment (CBT) in abstinent sub-
jects who also received an intensive psychological relapse pre-
vention program did not lead to better outcomes with respect to
reduction in either alcohol intake or severity of anxiety (Schadé
et al., 2005).
The role played by noradrenergic systems in both AUD and
anxiety remains to be more fully delineated. There is evidence,
however, of the involvement of these systems in both AUDs (Kash,
2012; Smith and Aston-Jones, 2008) and anxiety disorders
(Bremner, Krystal, Southwick, & Charney, 1996; Dell’Osso, Buoli,
Baldwin, & Altamura 2010; Rasmussen, Wilkinson, & Raskind,
2006). Thus, agents that modify the activity of brain noradren-
ergic systems may be value in the management of co-morbid AUD
and anxiety disorders. The present study examined the use of the
NSRI (norepinephrine serotonin reuptake inhibitor) antidepressant
venlafaxine for this purpose. Venlafaxine and its active metabolite,
O-desmethylvenlafaxine (ODV), are potent inhibitors of both
norepinephrine and serotonin uptake and weak inhibitors of
dopamine reuptake. It is of particular interest that the chronic
administration of venlafaxine does not alter basal levels of
norepinephrine within the prefrontal cortex, but does signiﬁcantly
lower the amount of this neurotransmitter released by a stressor
such as foot shock (Dazzi et al., 2002). Chronic administration of
venlafaxine has also been found to desensitize frontal cortical b-
adrenoreceptor-coupled adenylase cyclase systems in animals
selectively depleted of serotonin (Nalepa et al., 1998). These results
indicate that treatment with venlafaxine can reduce the activity of
noradrenergic receptor systems in certain conditions.
Several studies support the efﬁcacy of venlafaxine in general-
ized anxiety disorder (Allgulander, Hackett, & Salinas, 2001;
Gelenberg et al., 2000; Rickels, Pollack, Sheehan, & Haskins,
2000), panic disorder (Kjernisted & McIntosh, 2007; Liebowitz,
Asnis, Mangano, & Tzanis, 2009), social phobia (Stein, Pollack,
Bystritsky, Kelsey, & Mangano, 2005), and obsessive-compulsive
disorder (Denys, van der Wee, van Megen, & Westenberg, 2003;
Grossman & Hollander, 1996). The objective of the present inves-
tigationwas to determinewhether venlafaxine administered alone
or in combination with CBT using the Uniﬁed Protocol for the
Transdiagnostic Treatment of Emotional Disorders (UP) developed
by Barlow et al. (Barlow, Allen, & Choate, 2004; Barlow et al., 2011)
would reduce alcohol intake and anxiety compared to either CBTin combination with placebo (PLC) or PLC in combination with a
“control” behavioral therapy, i.e. progressive muscle relaxation
(PMR). For safety reasons all subjects were provided with an initial
platform treatment of motivational enhancement therapy (MET),
and were required to achieve four days of abstinence prior to
randomization to reduce the potential for alcoholevenlafaxine
interactions. The primary study hypothesis was that in comparison
to the PLC-PMR treatment condition, the other treatment combi-
nations would produce greater decreases during the treatment
period in both alcohol consumption and anxiety. It was also hy-
pothesized that the combination of venlafaxine and CBT would
show greater improvements in decreasing alcohol consumption
and anxiety than did these treatments when they were adminis-
tered alone.
Methods
Men and women were recruited into an outpatient anxiety
treatment program via radio, web, and newspaper advertisements.
Telephone screenings determined initial eligibility, and potential
research participants were invited to the Center for Anxiety and
Related Disorders at Boston University for a more extensive
assessment of alcohol use and emotional symptoms.
Inclusion criteria for subject eligibility included: 1) DSM-IV
diagnosis of alcohol abuse or dependence (alcohol use disorder:
AUD) and a diagnosis of anxiety disorder (panic disorder, social
phobia, or generalized anxiety disorder); 2) minimum age of 18
years; and 3) expressed desire to stop drinking alcohol completely
or to reduce alcohol consumption with the possible long-term goal
of abstinence. Exclusion criteria were: 1) DSM-IV diagnosis of
bipolar disorder, schizophrenia, bulimia/anorexia, dementia, or
other substance dependence, with the exception of nicotine,
marijuana, and caffeine dependence; 2) medical contraindication
to the use of venlafaxine; 3) currently taking anti-craving agents,
anti-depressant medications, or medication known to reduce
anxiety or alcohol consumption; 4) ongoing concurrent treatment
for alcohol problems; 5) currently taking medication that has sig-
niﬁcant interactions with venlafaxine; 6) previously received ven-
lafaxine; 7) currently prescribed medication with known abuse
potential; and 8) having experienced severe depression or suicidal
behaviors in the past 30 days.
The objective of this study was to compare the efﬁcacy and
safety of using venlafaxine and CBT to facilitate abstinence from
alcohol consumption in individuals with co-morbid AUDs and
anxiety disorders, as compared to combined treatment with pla-
cebo and PMR, the control treatment condition. The ﬂow diagram
for this study is presented in Fig. 1. This study, with respect to
medication therapy, followed a double-blind, randomized, placebo-
controlled study design.
All procedures used in this study were approved by the Boston
University and Boston University Medical Center‟s Institutional
Review Boards (IRBs), as well as the Central Texas Veterans Health
Care System IRB. Subjects provided informed consent in accordance
with IRB requirements. Participants who were unable to continue
the drug treatment due to adverse effects were discontinued from
the medication but continued to attend clinic for psychological
treatment and assessment.
Following telephone screening, subjects completed an in-clinic
baseline assessment to determine eligibility for inclusion in the
study. Eligible subjects were assigned to a counselor who provided
MET (Miller, 2004) to aid the subject in achieving an initial period
of four days of complete abstinence from alcohol (as a safety pre-
caution due to 50% chance of receiving venlafaxine). MET feedback
was given based on normative data published in the Combined
Behavioral Intervention Manual.
Fig. 1. Study ﬂow diagram.
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depending upon the client’s desire and ability to achieve the
required period of initial abstinence. These sessions were
completed within two to four weeks on average. Once subjects had
achieved the four day period of abstinence they completed a second
baseline assessment in which eligibility was re-assessed. Eligible
subjects were then randomized to receive one of four treatment
conditions: 1) Venlafaxine plus individualized CBT (VEN-CBT); 2)
Placebo medication plus CBT (PLC-CBT); 3) Venlafaxine plus PMR
(VEN-PMR); or 4) Placebo medication plus PMR (PLC-PMR). Each
treatment condition included a 7 day placebo run-in, and a 10 week
trial of venlafaxine or placebo followed by a 2-week taper. Indi-
vidual CBT was conducted in a standardized fashion, following the
Uniﬁed Protocol for the Transdiagnostic Treatment of Emotional
Disorders (UP) developed by Barlow and colleagues (Barlow et al.,
2004, 2011). The UP is a transdiagnostic, emotion-focused CBT
that emphasizes the adaptive, functional nature of emotions, and
seeks to identify and correct maladaptive attempts to regulate
emotional experiences. Development of this protocol began with
the distillation of key principles from traditional empirically-
supported CBT treatments integrated with innovations from the
ﬁeld of emotion science, incorporating and addressing deﬁcits in
emotion regulation common in emotional disorders (for discussion
on the development of the UP, see Wilamowska et al., 2010). In the
PMR condition, participants were told that PMR would be taught in
order to help them decrease stress and negative emotions. The PMR
conditions consisted of training in full-body muscle relaxation, as
well as cue-controlled muscle relaxation. Eleven sessions of eitherCBT or PMR were administered, each of which was approximately
50e60 min long.
Subjects received either a sustained release formulation of ven-
lafaxine (Effexor XR) ormatched placebo capsules. Activemedication
capsules each contained a 75 mg dose of venlafaxine. Medications
were supplied in identical appearing capsules. Amaintenance dose of
225 mg of venlafaxine was set as the target for subjects selected to
receive active medication. This dose has been shown to have efﬁcacy
in clinical trials of several anxiety disorders including general anxiety
disorder (Rickels et al., 2000), panic disorder (Pollack et al., 2007), and
social anxiety disorder (Liebowitz, Gelenberg, & Munjack, 2005).
In vitro evidence suggests that venlafaxine has greater afﬁnity for the
serotonin as opposed to the norepinephrine neuronal transporter
(NET) proteins (Roseboom & Kalin, 2000). These results indicate a
dose if venlafaxine in the range of 225mgwould beneeded to elevate
brain concentrations of this drug and its active metabolite O-des-
methylvenlafaxine to levels sufﬁcient to produce signiﬁcant inhibi-
tion of NETs.
Subjects received one placebo capsule daily during the ﬁrst
study week. In the second study week, one capsule of either ven-
lafaxine or placebo was provided daily to subjects. In Week 3 two
medication capsules were administered to subjects daily, and the
maintenance of 225 mg of venlafaxine or 3 placebo capsules were
to be taken daily thereafter. The study psychiatrists were allowed to
decrease the dose of medications received by subjects when it was
needed to reduce adverse drug effects. Pill counts were conducted
at each visit to encourage medication adherence. After completion
of Study Week 11, subjects’ medications were reduced over a 2-
week period by weekly reductions to a dose of two then one
capsule daily.
Assessments and measures
Anxiety and depression were measured using 5 instruments.
The clinician-administered Anxiety Disorders Interview Schedule-
IV: Lifetime Version (ADIS-IV-L; DiNardo, Brown, & Barlow, 1994)
was used to assess anxiety disorders, depressive disorders, and
AUD. The Anxiety Sensitivity Index (ASI; Reiss, Peterson, Gursky, &
McNally, 1986) was used to assess fears that anxiety symptoms
would have negative somatic, mental, or social consequences. The
Depression Anxiety Stress Scales (DASS; Lovibond & Lovibond,
1995) assessed depression, anxiety and stress responses. Finally,
the Hamilton Anxiety Rating Scale (Hamilton, 1959) and Hamilton
Depression Rating Scale (Hamilton, 1960) were clinician-
administered to assess symptoms of anxiety and depression,
respectively.
Threemeasures were used to assess alcohol use and craving. The
Alcohol Timeline Followback (TLFB; Sobell & Sobell, 1992) was
utilized to estimate participants’ daily drinking during the 90 day
period that preceded screening and at the beginning of each psy-
chotherapy session. The Alcohol Dependence Scale (ADS; Skinner &
Allen, 1982) was used to assess the severity of alcohol dependence
within the last 12months, and the Craving Desire Scale (CDS) is a 3-
item scale (namely, “1. I do want to drink now”, “2. I crave a drink
right now”, 3. “I have a desire for a drink right now”) that was used
to identify the degree of current alcohol craving, with responses
provided on a Likert-scale. A maximum score of 21 could be ob-
tained on this scale.
Participants were given a breathalyzer test and a blood pressure
test at psychotherapy sessions. CDS, DASS and TLFB data were ob-
tained prior to every treatment session. HAM-D and HAM-A data
were collected for behavioral treatment Sessions 1, 4, and 8.
Treatment sessions typically occurred during the corresponding
study week, but in some cases, because of missed appointments
behavioral treatment sessions took place in subsequent weeks.
Table 1
Subject description.
VEN-CBT PLC-CBT VEN-PMR PLC-PMR
N 24 21 14 22
Females 6 4 3 5
African American 2 1 0 2
White 21 18 12 19
Other 1 2 2 1
Alcohol dependence 23 16 14 20
Alcohol abuse 1 5 0 2
Panic disorder 2 2 3 1
GAD 18 14 8 15
Social phobia 11 10 7 13
Table 2
Means (SD) obtained for ADS scores and percent days drinking, percent days heavy
drinking, and mean drinks per day for the 90 day-long pre-screening period.
VEN-CBT PLC-CBT VEN-PMR PLC-PMR
ADS scores 15.0 (7.6) 15.8 (7.7) 16.6 (6.6) 16.1 (5.9)
Percent days drinking 72.0 (24.5) 76.0 (25.6) 88.1 (12.7) 76.5 (25.8)
Percent days heavy drinking 63.1 (28.0) 59.1 (33.7) 76.9 (19.1) 67.2 (28.6)
Drinks per day 8.4 (6.5) 7.0 (4.6) 9.6 (4.3) 9.7 (7.5)
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ment sessions were conducted by a research assistant one week
after the completion of the treatment protocol, then subsequently
at three, six, nine, and 12 months.
Data analysis
An intent-to-treat approach to analysis was used for this study.
A second analysis was performed for alcohol drinking variables for
subjects who reported taking at least one dose of study medication.
Demographic and diagnostic data are presented as means
(standard deviations), subject numbers, or as frequencies for each
treatment group. Treatment groupmeans were also determined for
other data used to characterize subjects including the ADS. The
total number of subjects meeting diagnostic criteria for AUD and
anxiety disorders was compiled. Baseline values for data with
continuous variables for each group were compared using one-way
analysis of variance (ANOVA). Comparisons of frequency data for
the groups were performed using chi-square tests. Adverse effects
were analyzed by pooling data into two groups based onwhether a
subject received venlafaxine or placebo. Between group compari-
sons were performed for moderate to severe adverse effects that
were rated as being medication related. The Fisher’s exact test was
used for group comparisons of adverse effects.
The patterns of subjects’ alcohol consumption were deter-
mined using TLFB derived values for percent days drinking,
percent days heavy drinking, and mean drinks consumed per day.
Weekly means were determined for these variables for the treat-
ment and post-treatment periods, while a single mean for these
variables was found for the 90 day-long pre-screening period. The
percentage of subjects for each treatment group reporting com-
plete abstinence during the last 5 weeks of the treatment period
i.e. Study Weeks 7e11, was determined based on the available
reported data from each subject. It was assumed that subjects for
whom TLFB was not available for any Study Week during this
period were not abstinent.
Treatment group drinking variables for both the treatment and
post-treatment data sets were analyzed using a two-way repeated
measures mixed models analysis (SAS version 9.2) with pre-
screening values used as covariates where appropriate. Study week
served as the within subject factor, while treatment condition was
the between group factor. Drinking data for the drug treatment
period were analyzed using data for the placebo run-in week and
for the last 5 weeks of the treatment period. The assessment period
using the last 5 weeks of medication administration was deter-
mined a priori and is consistent with current NIAAA studies of
medications that are expected to have a delayed onset of action in
alcoholism (Litten RA, personal communication). A second analysis
was conducted for a comparison of the placebo run-in week
drinking data with data obtained for the ﬁrst week of the follow-up
period. Values for percentages of abstinent subjects in each group
were compared using chi square tests.
Repeated measures mixed models analyses were also used to
evaluate all treatment period data obtained for the CDS, DASS,
HAM-A and HAM-D. Behavioral treatment Session, i.e. the partic-
ular therapy session prior to which assessments were adminis-
tered, was used as the within subject factor for these analyses.
When needed, within group time related changes between
behavioral treatment Session 1 and Session 11 values were
compared using paired t-tests for model generated least squares
means. An a value of less than 0.05was considered to be signiﬁcant.
When several comparisons were made the appropriate signiﬁcance
level was determined based on the Dunn-Sidak procedure. For 3
comparisons an unadjusted a value of less than 0.017 was regarded
as being signiﬁcant.Results
Subjects and subject compliance and motivation
The number of subjects assessed in each step of the study are
shown in Fig. 1. Not every subject completed the full course of
behavioral therapy during the 12 week medication treatment
period. These individuals received the balance of this therapy
following the medication treatment period. Follow-up data was
obtained after the completion of both medication and behavioral
treatments.
Subjects’ characteristics including mean ages, race, alcohol use
and anxiety diagnoses are presented in Table 1. There were no
signiﬁcant differences between the treatment groups with respect
to any of the variables presented in the table. Signiﬁcant differences
amongst groups were not found for baseline ASI, HAM-A, HAM-D
scores, the DASS subscale scores, or baseline measures of alcohol
consumption (Table 2).
Medication compliance based on pill count was not signiﬁcantly
different among the four treatment groups. Patients in three of the
treatment groups had medication compliance rates above 95%:
VEN-CBT: 96.89% [7.15]; PLC-CBT: 97.06% [7.41]; PLC-PMR: 95.39%
[9.62] while the VEN-PMR group had a compliance rate of 88.70%
[24.41]). Three subjects who, although randomized, reported not
taking even a single dose of study medication.
Alcohol consumption
The mean weekly percent days heavy drinking included in the
analysis are presented in Fig. 2 for the PLC-CBT and PLC-PMR
treatment groups. In the intent to treat analysis the
Time  Group interaction was found to be signiﬁcant for the
number of drinks consumed per day [F(15, 37) ¼ 1.73; p ¼ 0.044]
and approached signiﬁcance for the percent days heavy drinking
F(15, 337) ¼ 1.7; p ¼ 0.058]. In a second analysis, in which data for
three subjects who reported no use of any study medication or
placebo were excluded, the Time  Group interaction was signiﬁ-
cant for both number of drinks consumed per day [F(15,
327) ¼ 1.85; p ¼ 0.027] and the percent days heavy drinking F( 15,
327) ¼ 1.7; p ¼ 0.047]. For the three paired comparisons between
each “active” treatment group and the PLC-PMR group for percent
days heavy drinking, only the comparison with the PLC-CBT group
Fig. 2. Intent to treat data for weekly mean percent days heavy drinking for PLC-CBT
and PLC-PMR treatment groups for study weeks included in the analysis, i.e. Week 1
(the Placebo Re-In Week) and Weeks 7e11. p ¼ 0.01 for the Time  Group interaction
for paired comparisons in both the intent to treat analysis and the analysis of data for
subjects who used at least one dose of medication.
Fig. 3. Mean DASS-A anxiety (subscale scores obtained for Study Weeks 1e11 for each
of the treatment groups. VEN-CBT PLC-CBT VEN-PMR PLC-PMR.
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after correction for multiple comparisons in both analyses. None of
the other alcohol outcome measures differed signiﬁcantly between
groups in the mixed models analysis. In a post-hoc analysis the
proportion of subjects with a 50% reduction from prescreening
values in the percent days heavy drinking in week 11 were signif-
icant (p ¼ 0.01) only for the comparison between the PLC-CBT
group (90%) and PLC-PMR (53%). The number of subjects who
were abstinent during the entire last half of the drug treatment
periodwere two for the VEN-CBTgroup, four for the PLC-CBTgroup,
three for the VEN-PMR group, and one for the PLC-PMR group. Pair-
wise comparisons were not signiﬁcant for comparisons of the
proportion abstinent subjects in the groups between the PLC-PMR
group and any of the three other groups.Anxiety, depression, craving measures
Time effects, but not the Group or the Time  Group effects,
were signiﬁcant for the anxiety [F(10, 242) ¼ 5.01; p < 0.0001] (see
Fig. 3), depression [F(9, 211) ¼ 4.7; p < 0.0001], and stress
[F(9,209) ¼ 12.2; p, 0.0001] subscales of the DASS obtained for the
treatment period [see Fig. 3]. For the DASS anxiety subscale, model
generated least squaresmean values for the PLC-CBT, VEN-PMR and
PLC-PMR groups were signiﬁcantly lower for behavioral treatment
Session 11 as compared to Session 1 (See Fig. 3). Values for the
stress subscale of the DASS were signiﬁcantly less for Session 11
versus Session 1 for VEN-CBT [from 16.7 (7.6) to 8.1 (4.6)], PLC-CBT
[from 19.2 (9.1) to 9.6 (7.9)], VEN-PMR [from 21.5 (11.3) to 4.1 (7.9)]
and PLC-PMR [from 16.6 (8.2) to 11.2 (11.1)] groups. The Session 1e
Session 11 comparisons were signiﬁcant for the depression sub-
scale of the DASS only for PLC-CBT [from 12.8 (10.7) to 6.6 (7.6)] and
VEN-PMR [from 16.3 (12.5) to 6.1 (10.0)] groups, but again, as
indicated above, the Time  Group interaction was not signiﬁcant
for this measure.
For the HAM-A scale, the Time effects, but not the Group or the
Time  Group effects, were found to be signiﬁcant [F(2, 90) ¼ 16.4;
p < 0.0001]. The least squares means for the HAM-A scale declined
signiﬁcantly from Session 1 to Session 8 for the PLC-CBT [from 14.2
(7.3) to 9.1 (5.5)] and VEN-PMR [from 16.5 (6.8) to 7.9 (5.5)]treatment groups, but not for the VEN-CBT [from 13.5 (5.9) to 9.8
(6.9)] or the PLC-PMR [from 12.9 (4.1) to 9.1 (4.2)] groups. The Time
effect was also signiﬁcant for the HAM-D [F(2, 80.4) ¼ 8.8;
p ¼ 0.0003]. Session 1 to Session 8 comparisons for HAM-D least
squares means were signiﬁcant for the VEN-PMR group [ from 13.0
(7.2) to 5.9 (5.60)], but not the VEN-CBT [from 12.0 (5.7) to 8.8
(6.6)], PLC-CBT [from 11.7 (6.0) to 8.5 (4.6)], or PLC-PMR [from 13.6
(5.0) to 10.0 (6.2)] groups. Group effects and Time  Group in-
teractions were not signiﬁcant for the CDS measure of craving ob-
tained during the treatment period. The Time effect was signiﬁcant
for this analysis [F(10, 271) ¼ 3.9; p < 0.0001]. The decrease in CDS
least squares mean values from Session 1 to Session 11 was sig-
niﬁcant only for the VEN-CBT group [p¼ 0.011; from 8.6 (6.0) to 4.2
(1.9)] and for the PLC-PMR group (p ¼ 0.004), with scores declining
from 7.5 (5.1) to 4.3 (2.7).
Adverse effects
The proportion of subjects experiencing dry mouth was signif-
icantly greater (p ¼ 0.005) in the venlafaxine group (39.5%) than in
the placebo group (11.6%). Complaints of sexual dysfunction
occurred with signiﬁcantly greater frequency (p ¼ 0.001) in the
venlafaxine (34.2%) than in the placebo group (4.7%). Of note is that
suicidal ideation occurred in one subject in the venlafaxine group
and in none of the placebo patients. Although not signiﬁcantly
different, the proportion of subjects experiencing anorexia,
insomnia, and restlessness was twice as high in the venlafaxine
group (as compared to the placebo group).
Discussion
In the present study, subjects in the CBT-PLC group had
greater reductions in percent days heavy drinking in contrast to
the PLC-PMR comparison group. In contrast, to the hypotheses
that venlafaxine alone or CBT and active medication would
signiﬁcantly decrease alcohol consumption neither VEN-CBT nor
the VEN-PMR was superior to the placebo group on any alcohol
outcome measure. The actions of venlafaxine alone on alcohol
consumption were similar to those of the SSRI’s paroxetine
(Schadé et al., 2005) and ﬂuvoxamine (Thomas et al., 2008) in the
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ders in previous studies.
Anxiety, as measured by the anxiety subscale of the DASS,
decreased signiﬁcantly over the treatment period in the PLC-CBT,
VEN-PMR, and PLC-PMR groups. For each group, scores for DASS
stress subscales declined signiﬁcantly across the treatment period,
with no group differences being detected. As measured by the
HAM-A, anxiety also decreased signiﬁcantly from treatment ses-
sion one to eight in both the PLC-CBTand VEN-PMR groups (but not
PLC-PMR) with no differences between groups. Drinking was only
decreased in the PLC-CBT group, suggesting a possible dissociation
between changes in anxiety and in drinking. The ﬁnding that
anxiety was not signiﬁcantly reduced in the VEN-CBT group
compared to the PLC-PMR group is consistent with other evidence
that the addition of venlafaxine to CBT did not enhance the effects
of CBT alone for the treatment of generalized anxiety disorder
(Crits-Christoph et al., 2011).
One limitation of the present study is the small size of the
treatment groups. A major consequence of this deﬁciency was that
subject sample size became diminished during the follow-up
period to the point where it may have precluded meaningful be-
tween group comparisons in this period. A second major limita-
tion was the failure of our randomization procedure to lead to the
placement of equivalent numbers of subjects into each treatment
group. This resulted from our use of pre-determined randomiza-
tion of subjects based on their original assigned subject number
and an unexpected disparity in percentage of individuals who
were able to progress from MET therapy to the treatment phase of
the study amongst the subjects assigned to the difference treat-
ment groups.
The results of this study indicate venlafaxine is not superior to
placebo in its effects on alcohol consumption or anxiety in subjects
with co-morbid AUD and anxiety disorders. In contrast, CBT alone
may be of value in assisting individuals with co-morbid AUD and
anxiety disorders in reducing heavy drinking. We observed a sig-
niﬁcant reduction in anxiety in the absence of a similar ﬁnding for
alcohol consumption. This ﬁnding contradicts the notion that
lessening anxiety symptoms necessarily leads to better control of
drinking behavior. The goal of the Uniﬁed Protocol in this study was
not to directly treat the mood symptoms of each disorder, but
rather teach broad skills that address emotional regulation prob-
lems that underlie a cluster of internalizing disorders. This trans-
diagnostic approach is in part intended to reduce maladaptive re-
sponses to intense affect without speciﬁcally reducing or elimi-
nating this affect. The present ﬁndings suggest transdiagnostic
treatment that addresses emotional regulation problems may be of
value as a tool for the management of heavy drinking. Future
studies are necessary to replicate our ﬁndings, and should involve
larger samples sizes and comparisons with medications that
decrease anxiety and alcohol consumption.
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